Treating Addiction to Prescription Opioids

Area of Science:

• Pharmacology
• Addiction Medicine
• Public Health

Background:

• Traditional medication-assisted treatment (MAT) for opioid use disorder (OUD) primarily involved methadone maintenance or naltrexone after withdrawal.
• Buprenorphine, a partial μ-opioid receptor agonist, presents a safer alternative with lower abuse potential than methadone.
• Office-Based Opioid Addiction Treatment (OBOT) utilizing buprenorphine enhances patient accessibility to care.

Purpose of the Study:

• To highlight buprenorphine as a successful pharmacotherapy for OUD.
• To identify barriers to buprenorphine expansion in South Dakota, including provider shortages and concerns about diversion.
• To outline essential practices for safe and effective OBOT implementation.

Main Methods:

• Review of existing literature and clinical experience with buprenorphine for OUD.
• Identification of key challenges hindering widespread buprenorphine adoption.
• Proposal of best practices for OBOT, including patient selection and monitoring protocols.

Main Results:

• Buprenorphine demonstrates a favorable safety profile and efficacy in treating OUD.
• Significant barriers to buprenorphine access exist, including limited certified prescribers and insufficient knowledge.
• Concerns regarding diversion and abuse necessitate careful implementation strategies.

Conclusions:

• Expanding buprenorphine access through OBOT is crucial for improving OUD treatment in South Dakota.
• Implementing robust office practices, including urine drug screens and prescription monitoring, is vital to mitigate abuse potential.
• Integration with counseling and referral to higher levels of care ensures comprehensive patient management.